Prostate Cancer - Results from #160

Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis. December 22, 2022

Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression. December 22, 2022

Ambient exposures to selected volatile organic compounds and the risk of prostate cancer in Montreal. December 22, 2022

Clinical Validation of Artificial Intelligence-Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection. December 22, 2022

Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) T December 22, 2022

LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer December 21, 2022

Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy. December 21, 2022

Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions. December 21, 2022

Optimal assessment of quality of life for patients with prostate cancer. December 21, 2022

The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer. December 21, 2022

Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial. December 21, 2022

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma December 20, 2022

Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome. December 20, 2022

Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy. December 20, 2022

Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting. December 20, 2022

A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. December 20, 2022

Undergoing radical treatment for prostate cancer and its impact on wellbeing: A qualitative study exploring men's experiences. December 20, 2022

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. December 20, 2022

Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database. December 19, 2022

Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. December 19, 2022

Page 9 of 1276

email news signup